Janux Therapeutics stock
JANXNASDAQJanux Therapeutics, Inc., HealthcareISIN US47103J1051
33Score 33 out of 100, Weak
Price and trend
40 / 100
Price history
−60% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 25% below it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 30).
The price is 67% below its 52-week high. Largest decline in 5 years: 83% (August 2021 to November 2023).
Chart figures for advanced users
- SMA 50$16.97
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.37
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)30
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.50
- The lowest closing price of the last twelve months.
- Resistance$34.74
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Janux Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $703.61M, is number 214 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $10M (down 5.6% year on year) and a loss of $113.63M.
- For fiscal 2026, analysts expect on average revenue of $30.07M (up 200.7%) and adjusted earnings per share of −$1.75.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 644 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $945.72M, financial debt $20.38M.Stability 69
Weaknesses
- DilutionShare count up 49% since 2020.Capital allocation 18
- Loss-makingLoss of $99.85M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 60% over the last 12 months.Momentum 15
The score is held back by fundamentals and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 5.6% on the prior year. Revenue turned from negative at the start of the period to positive ($10M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 80%, operating −1577%, net −1136%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.34 (expected −$0.47)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.750.0%
- Revenue
- $30.07M0.0%
- Earnings per share
- −$2.670.0%
- Revenue
- $8.72M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $56,944 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Doyle Janeen NoelSale
2 Jun 2026, Chief Corp. & Bus. Dev. Ofcr
- Shares
- 4,059
- Price
- $14.03
- Value
- $56,944
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Janux Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Aura BiosciencesAURA $737.34M41
- Attovia TherapeuticsATTO $722.72M44
- OmniAbOABI $722.01M54
- Prime MedicinePRME $705.56M37
- Achieve Life SciencesACHV $697.68M41
- Nuvectis PharmaNVCT $695.69M46
- Ginkgo Bioworks HoldingsDNA $688.89M41
- Kura OncologyKURA $682.66M27
ETFs that hold Janux Therapeutics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.08% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.08% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.06% | 0.35% | €1.25B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Dec 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.